查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
抗病毒聯合療法市場，按藥物組合、副產品、分銷管道、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1351389

抗病毒聯合療法市場，按藥物組合、副產品、分銷管道、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Antiviral Combination Therapies Market, By Drug Combination, By Product, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 246 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022 年抗病毒聯合療法市場規模為 468.06 億美元，2023 年至 2030 年年複合成長率為 4.8%。

抗病毒聯合療法市場 - 市場動態：

  • 病毒感染的日益普及推動了市場的成長
  • 病毒感染的日益流行預計將在預測期內推動市場成長。每年，世界上相當一部分人口受到病毒性疾病的影響，包括 HIV/AIDS、肝炎、COVID-19、流感和皰疹。與單一藥物治療相比，抗病毒聯合藥物具有多種優勢，包括更能延遲或抑制抗藥性的發展。此外，抗病毒聯合療法已成為治療丙型肝炎和愛滋病毒等慢性病毒性疾病的黃金標準。抗病毒聯合藥物透過利用高效抗逆轉錄病毒療法來降低抗藥性和限制病毒傳播，在愛滋病毒治療中發揮重要作用。 NCBI稱，這些組合藥物除了有效治療流感等急性病毒感染外，還可降低抗藥性、抑制病毒繁殖、提高療效、降低死亡率。因此，預計這將推動市場成長。

抗病毒聯合療法市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球抗病毒聯合療法市場預計在預測期內（2023-2030 年）每年將以 4.8% 左右的年複合成長率成長
  • 由於病毒感染流行率不斷上升，抗病毒聯合療法產業預計將以顯著的速度成長。
  • 根據藥物組合，RTI/NNRTI 細分市場預計將在預測期內主導市場。
  • 從地區來看，預計北美將在預測期內主導市場。

抗病毒聯合療法市場細分分析：

  • 全球抗病毒聯合療法市場根據藥物組合、產品、分銷管道和地區進行細分。
  • 根據藥物組合，全球抗病毒聯合療法市場分為 RTI/NNRTI、整合酶抑制劑/NRTI、NRTI、NRTI/蛋白酶抑制劑等。預計 RTI/NNRTI 領域將在預測期內主導市場。 RTI/NNRTI 綜合藥物在抗病毒聯合治療領域，特別是在愛滋病毒/愛滋病的治療領域具有重要意義，可以歸功於這種擴張。它有助於阻止病毒擴散。此外，NRTI 是 RTI 的一個亞類，是模仿病毒 DNA 鏈中天然核苷酸的核苷類似物，其主要目標是阻止病毒 DNA 的產生。

抗病毒聯合療法市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。由於愛滋病毒、肝炎、流感等疾病的盛行率不斷上升，預計北美將在預測期內主導市場。此外，重要製藥企業的存在以及持續的研發項目也將大大促進北美市場的擴張。另一方面，預計亞太地區在預測期內將以最高的年複合成長率成長。該地區的市場成長歸功於製藥業的發展和政府措施的增加。

抗病毒聯合療法市場-競爭格局：

市場的主要參與者包括：默克公司、ViiV Healthcare、吉利德科學公司、艾伯維公司、楊森製藥、百時美施貴寶、勃林格殷格翰製藥公司、羅氏控股公司、Mylan NV 和 Cipla Ltd 。

最近的發展：

2023 年 2 月，Atea Pharmaceuticals 公佈了 AT-527（一種 COVID-19 容量治療藥物）的 2 期臨床研究的令人印象深刻的結果。一種名為 AT-527 的小化學物質會干擾 SARS-CoV-2 病毒的進入機制。這項突破可能會改善抗病毒組合治療的商業環境。

研究的主要特點：

  • 這項關於抗病毒聯合療法市場的建議研究提供了市場規模（百萬美元）、年複合成長率（CAGR%）和預測估計（2023-2030），以 2022 年為基準年
  • 該報告為客戶提供有關抗病毒聯合療法市場的最新趨勢見解。
  • 該研究報告闡明了不同細分市場/國家的潛在成長機會，並解釋了抗病毒聯合療法市場有吸引力的投資主張矩陣
  • 總體報告確定了新的投資機會、老牌參與者面臨的挑戰以及抗病毒聯合療法市場維持的成長因素
  • COVID-19 對抗病毒聯合療法市場規模、預測、年複合成長率和市場動態的影響將在研究範圍下詳細討論。也將詳細介紹新冠疫情後抗病毒聯合療法市場的情況。
  • 為了讓本報告的使用者全面了解抗病毒聯合療法市場，我們還包括了抗病毒聯合療法市場的競爭格局和關鍵創新者分析。
  • 該研究包括成長前景映射分析，其中所有行業細分都根據其市場規模、成長率和吸引力進行基準測試。
  • 該報告提供了主要市場參與者的詳細公司概況，這將幫助用戶了解抗病毒聯合療法市場參與者的財務資訊和策略舉措。
  • 此外，報告還公佈了全球和區域市場主要參與者的重要收購和合併、合作和合資、新產品推出、研發、區域擴張。
  • 全球抗病毒聯合療法市場報告主要針對該行業的各個利益相關者，包括供應商、投資者、新進業者、經銷商和財務分析師

目錄

第 1 章：抗病毒聯合療法市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 抗病毒聯合療法市場片段（按藥物組合）
    • 抗病毒聯合療法市場片段（按產品）
    • 按分銷管道分類的抗病毒聯合療法市場片段
    • 按國家/地區分類的抗病毒聯合療法市場片段
    • 按地區分類的抗病毒聯合療法市場片段
  • 競爭洞察

第 3 章：抗病毒聯合療法主要市場趨勢

  • 抗病毒聯合療法市場促進因素
    • 市場促進因素的影響分析
  • 抗病毒聯合療法市場限制
    • 市場限制影響分析
  • 抗病毒聯合療法的市場機會
  • 抗病毒聯合療法市場未來趨勢

第 4 章：抗病毒聯合療法產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：抗病毒聯合療法市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：抗病毒聯合療法市場格局

  • 2022 年抗病毒聯合療法市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：抗病毒聯合療法市場 - 按藥物組合

  • 概述
    • 按藥物組合分類的細分市場佔有率分析
    • 逆轉錄酶抑制劑/非逆轉錄酶抑制劑
    • 整合酶抑制劑/NRTI
    • 核苷類逆轉錄酶抑制劑
    • NRTI/蛋白酶抑制劑
    • 其他

第 8 章：抗病毒聯合療法市場 - 副產品

  • 概述
    • 按產品分類的細分市場佔有率分析
    • 品牌化
    • 通用的

第 9 章：抗病毒聯合療法市場 - 按分銷管道

  • 概述
    • 按分銷管道分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 其他

第 10 章：抗病毒聯合療法市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美抗病毒聯合療法主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物組合）
    • 北美市場規模和預測（按產品）
    • 北美市場規模和預測（按分銷管道）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲抗病毒聯合療法主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物組合）
    • 歐洲市場規模與預測（按產品）
    • 歐洲市場規模和預測（按分銷管道）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區抗病毒聯合療法主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 按藥物組合分類的亞太市場規模和預測
    • 亞太地區市場規模與預測（按產品）
    • 亞太地區市場規模和預測（按分銷管道）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗病毒聯合療法主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物組合）
    • 拉丁美洲市場規模與預測（按產品）
    • 拉丁美洲市場規模和預測（按分銷管道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲抗病毒聯合療法主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物組合）
    • 中東和非洲市場規模及預測（按產品）
    • 中東和非洲市場規模及預測（按分銷管道）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 抗病毒聯合療法產業

  • 競爭儀表板
  • 公司簡介
    • Merck & Co. Inc.
    • ViiV Healthcare
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Janssen Pharmaceuticals
    • Bristol Myers Squibb
    • Boehringer Ingelheim Pharmaceuticals Inc.
    • Roche Holding AG
    • Mylan NV
    • Cipla Ltd.

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1684

REPORT HIGHLIGHT

Antiviral Combination Therapies Market size was valued at USD 46,806 Million in 2022, expanding at a CAGR of 4.8% from 2023 to 2030.

Antiviral combination treatments, sometimes referred to as aggregate antiviral therapy (CART), include using several antiviral medications together to treat viral infections. This method includes combining various antiviral drugs that target various viral replication cycle components or individual viral traces to increase treatment efficacy and lower the risk of drug resistance. Antiviral aggregate treatment is necessary because viruses frequently have rapid mutation rates, which enable them to quickly adapt and build up resistance to single capsules.

Antiviral Combination Therapies Market - Market Dynamics:

  • The growing prevalence of viral infection drives the market growth
  • The growing prevalence of viral infection is expected to drive market growth during the forecast period. Each year, a sizable fraction of the world's population is impacted by viral illnesses including HIV/AIDS, hepatitis, COVID-19, influenza, and herpes. Compared to single-drug therapy, antiviral combination medicines have several advantages, including a greater ability to postpone or inhibit the development of drug resistance. Additionally, antiviral combination therapy has established itself as the gold standard for the treatment of chronic viral diseases including HCV and HIV. Antiviral combination medicines have been essential in the treatment of HIV by utilizing highly active antiretroviral therapy for lowering drug resistance and limiting virus transmission. In addition to effectively treating acute viral infections like influenza, these combination medicines, according to NCBI, can also lower drug resistance, inhibit viral reproduction, improve efficiency, and lower the mortality rate. Thus, this is expected to drive the market growth.

Antiviral Combination Therapies Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Antiviral Combination Therapies market is estimated to grow annually at a CAGR of around 4.8% over the forecast period (2023-2030)
  • The antiviral Combination Therapies industry is projected to grow at a significant rate owing to the growing prevalence of viral infection.
  • Based on the drug combination, the RTI/NNRTI segment is expected to dominate the market during the forecast period.
  • Based on region, North America is expected to dominate the market over the forecast period.

Antiviral Combination Therapies Market- Segmentation Analysis:

  • The Global Antiviral Combination Therapies Market is segmented based on Drug Combination, Product, Distribution Channel and Region.
  • Based on the drug combination, the global Antiviral Combination Therapies market is segmented into RTI/NNRTI, Integrase Inhibitor/NRTI, NRTI, NRTI/Protease Inhibitor, and Others. The RTI/NNRTI segment is expected to dominate the market during the forecast period. RTI/NNRTI aggregate medicines, which are significant in the field of antiviral combination treatments, notably in the treatment of HIV/AIDS, can be credited with the expansion. It aids in putting a stop to viral proliferation. Additionally, NRTIs, a subgroup of RTIs, are nucleoside analogs that imitate the natural nucleotides found in the viral DNA chain with the primary goal of stopping viral DNA production.

Antiviral Combination Therapies Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period due to the increasing prevalence of HIV, Hepatitis, Influenza and others. Moreover, the market's expansion in North America will also be significantly aided by the presence of important pharmaceutical businesses as well as continuing research and development projects. On the other hand, the Asia Pacific is expected to grow at the highest CAGR during the forecast period. The market growth in the region is attributed to the growing pharmaceutical industry and increasing government initiatives.

Antiviral Combination Therapies Market- Competitive Landscape:

The key players operating in the market are: Merck & Co. Inc., ViiV Healthcare, Gilead Sciences Inc., AbbVie Inc., Janssen Pharmaceuticals, Bristol Myers Squibb, Boehringer Ingelheim Pharmaceuticals Inc., Roche Holding AG, Mylan N.V. and Cipla Ltd.

Recent Developments:

In February 2023, Atea Pharmaceuticals unveiled impressive findings from a Phase 2 clinical study of AT-527, a COVID-19 capacity treatment. A small chemical called AT-527 interferes with the SARS-CoV-2 virus's entrance mechanism. This breakthrough may improve the commercial environment for antiviral combo treatments.

Key features of the study:

  • This proposed research study on Antiviral Combination Therapies market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Antiviral Combination Therapies market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Antiviral Combination Therapies market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Antiviral Combination Therapies market
  • Impact of COVID-19 on Antiviral Combination Therapies market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Antiviral Combination Therapies market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Antiviral Combination Therapies market, we have also included competitive landscape and key innovator analysis for the Antiviral Combination Therapies market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Antiviral Combination Therapies market.
  • In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Antiviral Combination Therapies market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET KEY PLAYERS

  • Merck & Co. Inc.
  • ViiV Healthcare
  • Gilead Sciences Inc.
  • AbbVie Inc.
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • Boehringer Ingelheim Pharmaceuticals Inc.
  • Roche Holding AG
  • Mylan N.V.
  • Cipla Ltd.

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DRUG COMBINATION

  • RTI/NNRTI
  • Integrase Inhibitor/NRTI
  • NRTI
  • NRTI/Protease Inhibitor
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY PRODUCT

  • Branded
  • Generic

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL ANTIVIRAL COMBINATION THERAPIES MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Antiviral Combination Therapies Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Antiviral Combination Therapies Market Snippet by Drug Combination
    • 2.1.2. Antiviral Combination Therapies Market Snippet by Product
    • 2.1.3. Antiviral Combination Therapies Market Snippet by Distribution Channel
    • 2.1.4. Antiviral Combination Therapies Market Snippet by Country
    • 2.1.5. Antiviral Combination Therapies Market Snippet by Region
  • 2.2. Competitive Insights

3. Antiviral Combination Therapies Key Market Trends

  • 3.1. Antiviral Combination Therapies Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Antiviral Combination Therapies Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Antiviral Combination Therapies Market Opportunities
  • 3.4. Antiviral Combination Therapies Market Future Trends

4. Antiviral Combination Therapies Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Antiviral Combination Therapies Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Antiviral Combination Therapies Market Landscape

  • 6.1. Antiviral Combination Therapies Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Antiviral Combination Therapies Market - By Drug Combination

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Combination, 2022 & 2030 (%)
    • 7.1.2. RTI/NNRTI
    • 7.1.3. Integrase Inhibitor/NRTI
    • 7.1.4. NRTI
    • 7.1.5. NRTI/Protease Inhibitor
    • 7.1.6. Others

8. Antiviral Combination Therapies Market - By Product

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
    • 8.1.2. Branded
    • 8.1.3. Generic

9. Antiviral Combination Therapies Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Others

10. Antiviral Combination Therapies Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Antiviral Combination Therapies Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Antiviral Combination Therapies Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Antiviral Combination Therapies Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Antiviral Combination Therapies Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Antiviral Combination Therapies Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Combination, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Antiviral Combination Therapies Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co. Inc.
    • 11.2.2. ViiV Healthcare
    • 11.2.3. Gilead Sciences Inc.
    • 11.2.4. AbbVie Inc.
    • 11.2.5. Janssen Pharmaceuticals
    • 11.2.6. Bristol Myers Squibb
    • 11.2.7. Boehringer Ingelheim Pharmaceuticals Inc.
    • 11.2.8. Roche Holding AG
    • 11.2.9. Mylan N.V.
    • 11.2.10. Cipla Ltd.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Antiviral Combination Therapies Market: Drug Combination Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Combination
  • TABLE Global Antiviral Combination Therapies Market, by Drug Combination 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Product Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Product
  • TABLE Global Antiviral Combination Therapies Market, by Product 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Antiviral Combination Therapies Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Antiviral Combination Therapies Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Antiviral Combination Therapies Market, by Region 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE North America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Europe Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Asia Pacific Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Latin America Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Drug Combination, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Product, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Antiviral Combination Therapies Market, by Distribution Channel, 2018-2030 (USD Million)